CERS - Cerus Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
6.69
-0.19 (-2.76%)
At close: 4:00PM EDT

6.70 +0.01 (0.15%)
After hours: 7:18PM EDT

Stock chart is not supported by your current browser
Previous Close6.88
Open6.82
Bid6.03 x 4000
Ask6.70 x 1000
Day's Range6.55 - 6.84
52 Week Range2.75 - 8.05
Volume899,675
Avg. Volume823,853
Market Cap895.216M
Beta (3Y Monthly)1.98
PE Ratio (TTM)N/A
EPS (TTM)-0.43
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.13
Trade prices are not sourced from all markets
  • Here's Why Cerus Corporation Stock Popped Today
    Motley Foolyesterday

    Here's Why Cerus Corporation Stock Popped Today

    Preliminary third-quarter results pleased the crowd at the company's annual investor meeting.

  • Business Wire2 days ago

    Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional Investor Meeting

    Cerus Corporation (CERS) is presenting its strategic roadmap and outlining its multi-year growth strategy at the 2018 Cerus Institutional Investor Meeting today in Boston. “Our efforts to establish the INTERCEPT Blood System as the standard of care for transfused blood components globally continue to gain traction,” commented William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “Our preliminary Q3 product revenue of $15.4 million underscores the strong market demand for the INTERCEPT Blood System during the quarter, especially in the U.S. Given our preliminary Q3 results, we are raising our full year product revenue guidance from a range of $56 million to $58 million to our new range of $58 million to $60 million, representing an increase of 33% to 38% compared to 2017 product revenue,” continued Greenman.

  • Business Wire6 days ago

    Cerus Announces Schedule of Presentations at the 2018 AABB Annual Meeting

    Cerus Corporation announced today its schedule of key events and presentations at the 2018 AABB Annual Meeting which is taking place in Boston on October 13 through October 16.

  • Business Wire7 days ago

    Dr. Laurence Corash Recognized With the Prestigious Dale A. Smith Memorial Award

    Cerus Corporation (CERS) today announced Dr. Laurence Corash, the Company’s co-founder and chief scientific officer has been awarded the prestigious Dale A. Smith Memorial Award by AABB’s National Blood Foundation. The award, which was created in 2002, honors Dale A. Smith, a long-time Baxter Health executive who was responsible for establishing the Fenwal Division. The award is presented to individuals or organizations in recognition of groundbreaking work in utilizing technology for innovation in transfusion medicine or cellular therapies.

  • Simply Wall St.7 days ago

    Cerus Corporation’s (NASDAQ:CERS) Most Important Factor To Consider

    Cerus Corporation (NASDAQ:CERS) shareholders, and potential investors, need to understand how much cash the business makes from its core operational activities, as well as how much is invested back into Read More...

  • Business Wire8 days ago

    Cerus Appoints Eric Bjerkholt to Board of Directors

    Cerus Corporation (CERS) today announced the appointment of Eric Bjerkholt to its Board of Directors. Mr. Bjerkholt currently serves as the chief financial officer of Aimmune Therapeutics, a San Francisco Bay Area biopharmaceutical company focused on the development of treatments to help protect people with food allergies. Mr. Bjerkholt brings over three decades of healthcare and biotech leadership experience to the Cerus Board, which has now been expanded to eight members.

  • Business Wire16 days ago

    Cerus to Host Institutional Investor Meeting

    Cerus Corporation today announced that it will host an Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston, Massachusetts.

  • Business Wire22 days ago

    Cerus to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

    Cerus Corporation today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, will present and provide a corporate update at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York City on Tuesday, October 2, 2018 at 3:25 p.m.

  • Business Wirelast month

    Cerus Appoints Timothy L. Moore to Board of Directors

    Cerus Corporation today announced the appointment of Timothy L. Moore to its Board of Directors. Mr. Moore, who currently serves as executive vice president, technical operations for Kite, a Gilead Company, brings over three decades of experience in engineering, manufacturing, and technical operations in the biopharmaceutical industry.

  • Cerus Corporation (NASDAQ:CERS): Is Now The Time To Bet On Healthcare?
    Simply Wall St.last month

    Cerus Corporation (NASDAQ:CERS): Is Now The Time To Bet On Healthcare?

    Cerus Corporation (NASDAQ:CERS), a US$1.04b small-cap, operates in the healthcare industry, which faces more complex and interdependent challenges, requiring multi-pronged, collaborative, and technology-enabled business models. Healthcare analysts are forecasting forRead More...

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Evertec, Cerus, REV Group, U.S. Silica, The Manitowoc, and World Fuel Services — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Evertec, ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CERS earnings conference call or presentation 2-Aug-18 8:15pm GMT

    Q2 2018 Cerus Corp Earnings Call

  • Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates (Revised)
    Zacks2 months ago

    Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates (Revised)

    Cerus (CERS) delivered earnings and revenue surprises of 9.09% and 11.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Cerus: 2Q Earnings Snapshot

    The Concord, California-based company said it had a loss of 10 cents per share. The biomedical products company posted revenue of $15.4 million in the period. Cerus expects full-year revenue in the range ...

  • Business Wire2 months ago

    Cerus Corporation Reports Second Quarter 2018 Results

    Product revenue increases 62% compared to 2017

  • ACCESSWIRE2 months ago

    Cerus Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Cerus Corporation (NASDAQ: CERS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:15 PM Eastern Time. ...

  • ACCESSWIRE3 months ago

    Free Stock Performance Review on Biogen and Three Additional Biotech Stocks

    This morning, WallStEquities.com observes BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), Biogen Inc. (NASDAQ: BIIB), and Cerus Corp. (NASDAQ: CERS). The Biotechnology industry consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development.

  • Zacks.com featured highlights include: OFG, Northern Oil, Sunrun, Cerus and Veracyte
    Zacks3 months ago

    Zacks.com featured highlights include: OFG, Northern Oil, Sunrun, Cerus and Veracyte

    Zacks.com featured highlights include: OFG, Northern Oil, Sunrun, Cerus and Veracyte

  • 5 Breakout Stocks Offering Stellar Returns
    Zacks3 months ago

    5 Breakout Stocks Offering Stellar Returns

    This involves zeroing in on stocks trading within a tight band and buying them when they move out of this band.

  • Business Wire3 months ago

    Cerus to Release Second Quarter 2018 Results on August 2, 2018

    Cerus Corporation announced today that its second quarter results will be released on Thursday, August 2, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 P.M.

  • Business Wire3 months ago

    New Navy Policy Implements Full Adoption of Pathogen-Reduced Apheresis Platelets Collected at U.S. Navy Blood Donor Centers

    Cerus Corporation announced today that the U.S. Department of the Navy will implement pathogen-reduction for all apheresis platelets collected at Navy Blood Donor Centers.

  • ACCESSWIRE4 months ago

    Free Technical Reports on Cerus and Three Additional Biotech Equities

    Losses were broad based as eight out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), and Cerus Corp. (NASDAQ: CERS).

  • ACCESSWIRE4 months ago

    Cerus Corporation Sees Product Demand Double, Revises Guidance Upward

    NEW YORK, NY / ACCESSWIRE / June 25, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cerus Corporation (CERS), a biomedical products company focused in the field of blood transfusion safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites that may be present in donated blood.

  • Business Wire4 months ago

    Cerus Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Congress of European Hematology Association

    Cerus Corporation announced that results from SPARC, the Company’s European Phase 3 study evaluating the efficacy and safety of INTERCEPT-treated red blood cells in thalassemia major patients, were presented today at the 23rd Congress of European Hematology Association in Stockholm Sweden in a poster presentation entitled, “A Randomized, Controlled, Phase III Study to Evaluate S-303/Glutathione Pathogen-Inactivated ...